Han‐Seung Park

ORCID: 0000-0003-3577-0665 · 1 paper in corpus · active 2018

Study types

  • article 1
article 2018
·doi:10.1182/blood-2018-99-115931

Abstract Background Improvement of cytopenia is one of the primary treatment purposes for patients with the lower-risk myelodysplastic syndrome (MDS). Androgens have been used for the treatment of aplastic anemia, immune thrombocytopenia, a…